N. Anthony Coles
2020 - Cerevel Therapeutics Holdings
In 2020, N. Anthony Coles earned a total compensation of $2.7M as Chairperson and Chief Executive Officer at Cerevel Therapeutics Holdings, a 74% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $444,000 |
|---|---|
| Option Awards | $1,499,999 |
| Salary | $600,000 |
| Other | $198,000 |
| Total | $2,741,999 |
Coles received $1.5M in option awards, accounting for 55% of the total pay in 2020.
Coles also received $444K in non-equity incentive plan, $600K in salary and $198K in other compensation.
Rankings
In 2020, N. Anthony Coles' compensation ranked 4,205th out of 13,090 executives tracked by ExecPay. In other words, Coles earned more than 67.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,205 out of 13,090 | 68th |
Division Manufacturing | 1,702 out of 5,624 | 70th |
Major group Chemicals And Allied Products | 659 out of 2,257 | 71st |
Industry group Drugs | 563 out of 1,957 | 71st |
Industry Pharmaceutical Preparations | 429 out of 1,462 | 71st |
Source: SEC filing on April 28, 2021.
Coles' colleagues
We found four more compensation records of executives who worked with N. Anthony Coles at Cerevel Therapeutics Holdings in 2020.
News
Cerevel Therapeutics Holdings CEO N Coles' 2021 pay jumps 990% to $8.1M
April 28, 2022
KINETA CEO Richard MDPhD receives $4.5M in 2021
April 25, 2022
Cerevel Therapeutics Holdings Chief Corporate Affairs Officer Kathleen MA receives $3.7M in 2020
April 28, 2021
KINETA CEO Meenu Chhabra's 2020 pay jumps 65% to $3.3M
April 22, 2021